ADVA launches TeraFlex™ CoreChannel™ for industry’s longest 800G reach
8.6.2021 10:00:00 EEST | Business Wire | Press release
ADVA (FSE: ADV) today launched its FSP 3000 TeraFlex™ CoreChannel™, giving internet content providers (ICPs) and communication service providers (CSPs) the power to transmit 800Gbit/s over greater distances than ever before. Using 140GBd sub-carrier technology, the new CoreChannel™ sled offers the market’s longest reach for a single-channel 800Gbit/s solution, enabling ultra-high-capacity transport over existing and new network infrastructure of more than 1,600km. This provides an improvement in reach of over 50% compared with 95GBd technologies. As well as the longest reach, the sled offers the highest client port flexibility. TeraFlex™ CoreChannel™ can support 400GbE, 100GbE and 10GbE or a mixture of client speeds. The solution is now being trialed by major carriers and R&E network operators.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210608005217/en/
ADVA’s CoreChannel™ transmits 800G data channels 50% farther than any competing solution (Photo: Business Wire)
“Network operators across the planet have been harnessing our FSP 3000 TeraFlex™ to unlock the full potential of their fiber assets. Our compact, plug-and-play terminal offers a simple and cost-efficient way to maximize the capacity of optical infrastructure. Today we’re making it even more powerful with the introduction of our CoreChannel™ sled. Customers can now transport data at 400Gbit/s and 800Gbit/s over longer distances than ever before with a solution that delivers the lowest possible cost per bit per kilometer,” said Christoph Glingener, CTO, ADVA. “Our FSP 3000 TeraFlex™ CoreChannel™ technology offers an enormous boost to operators transmitting services across countries and continents. What’s more, long-haul transport with TeraFlex™ CoreChannel™ is even more efficient and reliable thanks to its superior link signal-to-noise (SNR) requirements and higher network performance.”
The launch of ADVA’s CoreChannel™ sled positions the FSP 3000 TeraFlex™ as the industry’s most efficient high-capacity platform for all applications from metro to core to ultra-long-haul submarine links. Compatible with deployed infrastructure, the new solution can transmit 800Gbit/s over more than 1,600km. What’s more, TeraFlex™ CoreChannel™ delivers industry-leading SNR requirements making it resilient to transmission impairments. Along with the bandwidth flexibility and fractional QAM capabilities of the TeraFlex™ terminal, this ensures 800Gbit/s transport with highest efficiency, highest performance and lowest cost. Featuring multi-rate client support, the CoreChannel™ sled can transport any mix of 400GbE, 100GbE and 10GbE services, providing customers with flexibility and protecting their investment as they migrate to higher speeds.
“The launch of our FSP 3000 TeraFlex™ CoreChannel™ changes the game for terrestrial long-haul and regional transport. It gives ICPs and CSPs the ability to inject new capacity into their deployed networks. Now they can drive line speeds of up to 800Gbit/s over distances 50% longer than can be achieved with 95GBd solutions. That advantage will be key to tackling ever-increasing data growth without adding significant cost and complexity,” commented Cornelius Fürst, director, product line management, ADVA. “With its unrivaled reach, multi-rate client flexibility and rich performance settings, TeraFlex™ CoreChannel™ redefines the economics of backbone networks. It will play a key role in accelerating the delivery of high-bandwidth, feature-rich services over ultra-long-haul global infrastructure. And because it can be flexibly configured for lower data rates, it supports a smooth transition to high-speed connectivity.”
Watch this video for more information on the FSP 3000 TeraFlex™ CoreChannel™: https://adva.li/fsp-3000-teraflex-corechannel-product-video.
Further details are also available in this Tech Cam video: https://adva.li/fsp-3000-teraflex-corechannel-tech-cam.
Supporting slides can be viewed here: https://adva.li/fsp-3000-teraflex-corechannel-slides.
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210608005217/en/
Contact information
For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com
For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
